Know Cancer

forgot password

In Vivo and In Vitro Pharmacology of Sirolimus in Subjects With Basal Cell Nevus Syndrome

Phase 1
18 Years
Open (Enrolling)
Neoplastic Syndrome, Non-Melanomatous Skin Cancer

Thank you

Trial Information

In Vivo and In Vitro Pharmacology of Sirolimus in Subjects With Basal Cell Nevus Syndrome



- Compare messenger RNA and protein expression patterns in patients with basal cell nevus
syndrome (BCNS) vs in cultured cells of healthy participants (control) before treatment
to identify a set of genes that are differentially expressed in BCNS.

- Assess the effects of topical sirolimus on gene expression (genes identified in the
primary objective) in vivo using keratinocytes, fibroblasts, and lymphocytes from
patients with BCNS and from healthy participants (controls) by targeted expression

OUTLINE: Patients and healthy participants receive topical sirolimus ointment twice daily
for 12 weeks.

Blood and skin biopsies are obtained at baseline and at week 12 for gene and protein
expression studies. Alterations in RNA are measured by microarray analysis. Alterations in
protein expression are measured by 2-dimensional gel electrophoresis and matrix-assisted
laser desorption ionization time-of-flight mass spectrometry.

After completion of study therapy, patients and healthy participants are followed at 4

PROJECTED ACCRUAL: A total of 16 patients and healthy participants will be accrued for this

Inclusion Criteria


- Patient

- Confirmed diagnosis of basal cell nevus syndrome (BCNS)

- Known patched (PTCH) gene mutation

- Must have full sequence of coding exons with intron/exon junctions in the
PTCH gene OR prior genetic testing confirming PTCH mutation by the Yale
University DNA Diagnostics Laboratory

- Age- and sex-matched healthy participant (control)

- Unaffected relative of patient OR normal healthy volunteer with no family
history of BCNS or features of BCNS

- No unrelated healthy participant meeting any of the following clinical
criteria for BCNS:

- Lamellar calcification of the falx cerebri

- Prior odontogenic keratocyst or any jaw cyst for which a
histopathologic diagnosis cannot be ascertained

- Palmar or plantar pits typical of BCNS

- More than 3 basal cell carcinomas (BCC) in a lifetime or 1 BCC under
the age of 30

- History of medulloblastoma

- No unrelated healthy participant with 2 or more of the following features:

- History of ovarian or cardiac fibroma

- Mesenteric or pleural cysts

- Polydactyly

- Macrocephaly determined after adjustment for height

- Craniofacial features of BCNS, including cleft palate, frontal
bossing, hypertelorism, iris coloboma or other developmental defects
of the eye, or coarse facies

- Vertebral anomalies, including spina bifida occulta outside the lumbar

- Bifid or splayed ribs

- Other radiographic findings, including bridging of the sella turcica,
nonlamellar calcification of the falx cerebri, or flame-shaped
lucencies in the phalanges = 1-3 BCCs over the age of 30


- WBC ≥ 4,000/mm³

- Neutrophil count ≥ 2,000/mm³

- Platelet count ≥ 150,000/mm³

- Hemoglobin ≥ 11.5 g/dL

- Bilirubin 0.3-1.0 mg/dL

- AST 17-59 U/L

- PTT 10-13 seconds OR INR 1.0-1.4

- Creatinine clearance > 50 mL/min

- Cholesterol < 350 mg/dL

- Triglycerides < 400 mg/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile participants must use effective contraception for ≥ 1 month before, during,
and for ≥ 12 weeks after study treatment

- No active infection

- No alcohol or drug abuse

- No psychiatric disorder or mental deficiency that would preclude study compliance

- No uncontrolled hypertension (i.e., blood pressure > 140/90 mm Hg on > 2

- No chronic active infection requiring treatment

- No untreated reactive purified protein derivative of tuberculin (PPD)

- No HIV-1 infection

- No infection requiring antibiotics within the past 30 days

- No other skin disease affecting broad areas of the body, including the region to be
treated and biopsied

- No known hepatitis B or C infection (detectable RNA off antiviral therapy)

- No immune deficiency disorder

- No known hypersensitivity to sirolimus or macrolide antibiotics (e.g., erythromycin,
azithromycin, or clarithromycin)

- No cancer within the past 5 years except basal cell skin cancer


- At least 1 month since prior investigational drugs

- No concurrent dietary supplements, including Hypericum perforatum (St. John's wort)
or megadose vitamins

- No other concurrent immunosuppressive medications, including corticosteroids

- No concurrent medications known to interfere with sirolimus metabolism

- No concurrent anticoagulants

- No concurrent acetylsalicyclic acid or other drugs affecting platelet function or

- No routine (i.e., > 2 doses/week) use of nonsteroidal anti-inflammatory drugs

- No drugs or substances that would effect sirolimus blood concentrations, including
any of the following:

- Nicardipine

- Verapamil

- Clotrimazole

- Fluconazole

- Itraconazole

- Troleandomycin

- Cisapride

- Metoclopramide

- Clarithromycin

- Erythromycin

- Bromocriptine

- Cimetidine

- Danazol

- HIV-protease inhibitors (e.g., ritonavir or indinavir)

- Phenobarbital

- Carbamazepine

- Phenytoin

- Rifabutin

- Rifapentine

- Grapefruit juice

- Vaccinations (especially live vaccines)

Type of Study:


Study Design:

Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

Alterations in RNA as measured by microarray analysis

Safety Issue:


Principal Investigator

Allen E. Bale, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Yale University


United States: Federal Government

Study ID:




Start Date:

Completion Date:

Related Keywords:

  • Neoplastic Syndrome
  • Non-melanomatous Skin Cancer
  • basal cell carcinoma of the skin
  • nevoid basal cell carcinoma syndrome
  • Basal Cell Nevus Syndrome
  • Neoplasms
  • Skin Neoplasms